“When did you last have a conversation about quality, compliance or traceability that was not triggered by something going wrong?”

I ask every senior life sciences executive I meet a version of that question and the answer is almost always the same. There is a pause, then a search for an example that never quite arrives.

That pause tells you everything about the state of operational intelligence in pharmaceutical and medical device manufacturing today.

It also points to the leadership mandate now taking shape across the industry: Build to Sense. Ready to Act.

For life sciences manufacturers, it means building manufacturing environments that can sense process drift, quality risk, compliance erosion and traceability gaps early enough for leaders to act before they become deviations, observations, investigations or patient-impacting events.

The life sciences industry is built to respond well. We have sophisticated incident response frameworks, robust Corrective and Preventive Action (CAPA) systems, mature regulatory remediation processes and investigation teams with deep institutional memory. When something goes wrong, we mobilize with speed and rigor.

In pharmaceutical manufacturing, these signals may appear as process variability, environmental excursions or batch genealogy gaps. In medical device operations, they may emerge as UDI traceability inconsistencies, device history record (DHR) discrepancies, sterile packaging quality risks or early indicators from complaint trending data. In either context, the challenge remains the same: identifying risk early enough to act before it becomes a quality or compliance event.

What we have not built, at least not yet and not at scale, is the infrastructure for this kind of early visibility. The ability to know, in real time, that a process is drifting before it becomes a deviation, that a compliance behavior is eroding before it becomes an observation, and that a gap in material genealogy exists before it becomes an investigation.

This is the gap Physical AI begins to close. Not by replacing quality systems, but by making them earlier, more visible, measurable and more continuous. For an industry where trust depends on demonstrable quality, traceability, patient safety and regulatory compliance, that distinction matters.

The regulatory framework is shifting

Regulators worldwide are steadily shifting from periodic compliance verification to an increasing expectation of continuous process assurance, data integrity oversight and proactive quality management. The FDA’s sustained focus on data integrity, real-time monitoring and process analytical technologies is not a passing regulatory priority. It reflects a broader move toward greater operational visibility, proactive quality management and continuous process assurance.

At the same time, the technology needed to close this gap has arrived, not in prototype form and not as a research project, but as production-grade capability that can support  GxP-compliant deployment and validation in pharmaceutical and medical device manufacturing environments today.

Regulatory expectations are moving with technological capability. DIA’s 2025 perspective on AI governance in life sciences underscores that robust governance is critical to translating regulatory requirements and ethical principles into operational practice. It also points to a persistent readiness gap, with many organizations still in the early stages of establishing the governance frameworks needed to scale AI responsibly and effectively.

In regulated manufacturing environments, this shift is becoming a quality and lifecycle governance issue. ISPE’s 2025 guidance on AI-enabled computerized systems in GxP areas emphasizes the need to protect patient safety, product quality and data integrity. It also highlights design, development, operation, monitoring, maintenance and ongoing control across the AI-enabled system lifecycle.

Many life sciences organizations understand this direction. The harder truth is that understanding the shift is not the same as being ready for it. The gap between regulatory expectation and operational reality is widening rather than narrowing.

The Physical AI era has moved beyond the plant floor

The inflection point is not exclusive to life sciences. HCLTech’s The AI Impact Imperatives, 2026 report, based on a survey of 467 senior technology and business executives worldwide, found that 90% of organizations now consider Physical AI critical or important to their success over the next three years, a signal of how quickly the category has moved from experimental interest to executive priority.

However, the same study reveals a discrepancy between deployment and conviction. Organizations still researching, evaluating, piloting or deploying their first Physical AI systems outnumber those running many systems in full production by more than four to one.

The plant floor is one of the most obvious immediate opportunities for the technology. In the same research, 55% of respondents cited manufacturing as an area that stands to benefit, trailing only logistics and supply chain, field operations and facilities management.

The business impact is measurable. Our delivery modeling demonstrates that, even before factoring in support cost reduction or prevented incidents, a 10,000-person organization can restore roughly $2.4 million in productive capacity annually by recovering just 10 minutes of productive time per employee each week through proactive support, self-repair automation and real-time experience insights.

The organizations that have moved first are already seeing results that go well beyond faster inspections. Among those with Physical AI systems in production, 73% report reduced R&D costs, 68% report measurable improvements in physical safety, 63% cite better resource utilization and 62% report improved production line uptime.

For me, the important point is not that the technology works in isolated use cases. It is that the early evidence now points to a broader operational shift. Physical AI is becoming a capability layer that can improve how organizations see, decide and act across physical environments.

This data validates what we consistently observe in the production of pharmaceuticals and medical devices: the technology itself is rarely the only obstacle to achieving Physical AI at scale. The harder work is solving governance, integration, validation and adoption in a way that reflects the realities of a GxP environment.

What leaders are underestimating

• The compounding nature of operational intelligence

Most organizations evaluate Physical AI one deployment at a time: install vision inspection on a line, measure the defect reduction, book the return. In my view, that framing is too narrow.

Every process parameter, operator action and equipment signal it captures builds a data foundation that compounds over time, well beyond the original use case. A first deployment may improve inspection. The next may improve traceability. Over time, the organization begins to build a more intelligent operating layer, where each use case strengthens the next.

• The validation barrier is lower than the industry believes

Validation is not easy and no serious leader in this industry should pretend otherwise. But it is no longer the barrier many organizations assume it to be.

Leading Physical AI platforms are increasingly being designed with validation accelerators, IQ/OQ/PQ templates and governance architectures aligned to 21 CFR Part 11 and Annex 11. Deployment timelines once considered aspirational are now becoming achievable when the platform, partner and deployment model have been designed for regulated environments from the beginning.

The question is no longer whether Physical AI can be validated. The question is whether organizations are choosing solutions that were built with validation, governance and lifecycle control as core design principles, not afterthoughts.

Patient safety is not weighted heavily enough in the business case

The patient safety case for Physical AI is not separate from the business case. It is the strongest version of it. When a system can detect risk earlier, reduce avoidable variation and strengthen traceability, it is protecting both enterprise value and the patient promise at the centre of this industry.

For medical device manufacturers, this could include earlier detection of implant manufacturing variability, improved traceability across UDI records, enhanced monitoring of sterile packaging integrity and faster identification of emerging complaint trends that may indicate quality risks in the field.

The leadership implications

The leadership question is different depending on where you sit, but the direction of travel is the same. Physical AI is shifting quality, compliance and operational performance from retrospective review to real-time assurance.

For Chief Quality Officers, quality architecture is evolving from a gate at the end of the process to a continuous property of the process itself. That requires rethinking not just technology investments, but team structures, quality system governance and the relationship with regulators.

For plant and site leaders, the efficiency and compliance dividends of Physical AI are significant enough that the investment case is no longer theoretical. The real question is deployment sequencing: which capabilities, at which sites, and in what order.

For digital manufacturing leaders, Physical AI offers a way out of pilot fatigue. Purpose-built Physical AI for life sciences can help address validation, business case and integration challenges at the design level more systematically, rather than leaving them to be solved project by project.

For the C-suite broadly, the manufacturers who define life sciences manufacturing excellence in 2030 are making their Physical AI infrastructure investments now, in 2026. The competitive gap will not be created by one deployment alone. It will be created by the accumulated intelligence, validated playbooks and operating confidence that early movers build over time.

The practical first step

For most organizations, the practical entry point is a structured assessment: a rigorous review of current quality, compliance, safety and traceability performance measured against a Physical AI capability map.

This identifies the highest-impact, lowest-complexity deployment opportunities that can yield quantifiable returns within nine to 12 months while laying the groundwork for more extensive transformation.

For biopharmaceutical manufacturers, these opportunities often emerge around process monitoring, batch genealogy, environmental monitoring, deviation prediction and contamination risk detection.

For medical device manufacturers, these opportunities often emerge around vision-based inspection, UDI traceability, device history record verification, complaint trending analytics and sterile manufacturing operations.

Two factors constantly surprise organizations that have done this work: the amount of value available in the first deployment phase and the speed at which they can advance beyond their expectations.

The best starting point is rarely the most ambitious use case. It is the use case that proves the model, builds internal confidence and creates the foundation for scale. That is how organizations move from isolated pilots to an operating environment that is truly built to sense and ready to act.

From principle to implementation

For life sciences manufacturers, becoming built to sense and ready to act requires more than deploying isolated AI use cases. It requires an integrated capability layer across sensing, inspection, traceability, edge intelligence, digital operations and lifecycle governance.

This is where the choice of technology architecture and partner becomes critical. Physical AI in regulated manufacturing must be designed around GxP validation, data integrity, auditability, system lifecycle control and measurable business impact from the beginning.

HCLTech’s Physical AI portfolio, including VisionX Edge, VisionX.QA, TraceX, Kinetic AI, iEdgeX and SmarTwin, is purpose-built to help pharmaceutical and medical device manufacturers move from reactive quality and compliance models to more continuous, intelligent and validated operating environments. Backed by the HCLTech Physical AI Innovation Lab, built in collaboration with NVIDIA, the portfolio brings together the capabilities required to sense earlier, act faster and scale responsibly.

The next standard of trust

One promise underpins the life sciences industry’s relationship with regulators, healthcare systems and patients: every unit released to the market must be safe, effective and traceable.

Physical AI strengthens that promise by helping manufacturers sense risk earlier, act faster and demonstrate trust more continuously. For leaders, this is not simply a technology decision. It is a shift in how quality, compliance and patient safety are engineered into the operating model.

The organizations that make this shift now will be better positioned to define the next standard of manufacturing trust in life sciences.